Decoding ADC ADME With Tailored Strategies

Antibody–drug conjugates (ADCs) have emerged as one of the fastest-growing therapeutic modalities, offering the precision of targeted biologics combined with the potency of cytotoxic small molecules. Despite their clinical promise, ADCs present significant scientific and regulatory challenges in absorption, distribution, metabolism, excretion (ADME), and drug–drug interaction (DDI) characterization. Their complex tripartite structures require advanced bioanalytical strategies capable of quantifying intact ADCs, antibodies, and free payloads simultaneously. In addition, understanding payload release mechanisms from both cleavable and non-cleavable linkers is critical for assessing efficacy, systemic exposure, and toxicity. The low circulating concentrations of payload-related components further demand highly sensitive analytical technologies, including advanced LC-HRMS methods.

Compounding these challenges, evolving and limited ADC-specific regulatory guidance places greater emphasis on robust, scientifically justified ADME and DDI data packages. BioDuro addresses these complexities through tailored decision frameworks and fit-for-purpose ADME strategies that support efficient, data-driven ADC development from early discovery through regulatory submission.